DNase I Inhibitors
1 drugsAbout DNase I
Deoxyribonuclease I (DNase I) is an endonuclease enzyme that degrades DNA, playing a crucial role in various biological processes by cleaving DNA. Understanding its function can pave the way for developing novel therapies by manipulating DNA degradation processes.
DNase I's ability to cleave DNA is crucial in various biological processes, and understanding its role can pave the way for developing novel therapies. Currently, there is no genetic evidence data available linking DNase I to specific diseases.
DNase I is targeted by one FDA-approved drug, PULMOZYME (Roche), a biologic used in respiratory indications since 1993. Further exploration of this target could lead to new treatments beyond respiratory illnesses.
Top DNase I Drugs
Roche is the only company with an approved drug targeting DNase I.
Low competition suggests high entry barriers or limited perceived opportunity.
DNase I Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DNase I, using enzyme modality.
The lack of modality diversity indicates whitespace opportunity for small molecules or other approaches.
DNase I Clinical Trials 22 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNase I. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 | 50% |
| Phase 2 | 9 | 4 | 0 | 5 | 100% |
| Phase 3 | 5 | 2 | 2 | 1 | 50% |
| Phase 4 | 6 | 4 | 2 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DNase I Drug Approval Timeline (1993 - 1993)
PULMOZYME was approved in 1993 and remains the only approved drug.
The single approval nearly 30 years ago suggests a saturated market or limited innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 19 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNase I. A trial counts if an approved drug acting on DNase I is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.